Literature DB >> 19099278

[Conn's syndrome].

E Born-Frontsberg1, M Quinkler.   

Abstract

The primary hyperaldosteronism (PHA) is the most prevalent form (8-10%) of secondary causes of hypertension among hypertensive subjects. This will result in 2 to 2.5 million people suffering from PHA in Germany. Screening for PHA should be performed by measuring the aldosterone-renin ratio in the morning. The current antihypertensive medication should be taken into account. A suspicious ratio must lead to a confirmatory test to validate the diagnosis of PHA. For further PHA subtype investigation adrenal imaging is performed using CT or MRI. Adrenal venous sampling is often required to definitively confirm uni- or bilateral aldosterone hypersecretion. The aldosterone-producing adenoma (Conn's syndrome) is primarily cured by endoscopical unilateral adrenalectomy. Bilateral hyperplasia, which is found in two-thirds of primary hyperaldosteronism, is treated primarily by a mineralocorticoid receptor antagonist (12.5-100 mg/day spironolactone). The start of medication should be closely monitored by serum electrolyte and creatinine controls.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19099278     DOI: 10.1007/s00108-008-2195-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  27 in total

1.  Is it time for spironolactone therapy in dialysis patients?

Authors:  Adrian Covic; Paul Gusbeth-Tatomir; David J A Goldsmith
Journal:  Nephrol Dial Transplant       Date:  2006-01-31       Impact factor: 5.992

Review 2.  [Diagnosis of primary hyperaldosteronism].

Authors:  Sven Diederich; Martin Bidlingmaier; Marcus Quinkler; Martin Reincke
Journal:  Med Klin (Munich)       Date:  2007-01-15

3.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.

Authors:  Paul Milliez; Xavier Girerd; Pierre-François Plouin; Jacques Blacher; Michel E Safar; Jean-Jacques Mourad
Journal:  J Am Coll Cardiol       Date:  2005-04-19       Impact factor: 24.094

4.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

5.  Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension.

Authors:  Monique N Pratt-Ubunama; Mari K Nishizaka; Robyn L Boedefeld; Stacey S Cofield; Susan M Harding; David A Calhoun
Journal:  Chest       Date:  2007-02       Impact factor: 9.410

Review 6.  A review of the medical treatment of primary aldosteronism.

Authors:  P O Lim; W F Young; T M MacDonald
Journal:  J Hypertens       Date:  2001-03       Impact factor: 4.844

7.  Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

Authors:  Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

8.  Efficacy and tolerance of spironolactone in essential hypertension.

Authors:  X Jeunemaitre; G Chatellier; C Kreft-Jais; A Charru; C DeVries; P F Plouin; P Corvol; J Menard
Journal:  Am J Cardiol       Date:  1987-10-01       Impact factor: 2.778

9.  Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Susan M Harding
Journal:  Chest       Date:  2004-01       Impact factor: 9.410

Review 10.  Primary aldosteronism: part II: subtype differentiation and treatment.

Authors:  G P Rossi; T M Seccia; A C Pessina
Journal:  J Nephrol       Date:  2008 Jul-Aug       Impact factor: 3.902

View more
  1 in total

1.  [Pareses, myalgias, and massive CK elevation: a severe neurological disorder?].

Authors:  Johannes Steinfurt; Markus C Müller; Anke Seidel; Richard Salm; Andreas Ochs
Journal:  Med Klin (Munich)       Date:  2010-07-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.